Medicine and Dentistry
Multiple Myeloma
100%
Disease
38%
Light Chain
26%
Malignant Neoplasm
25%
Chimeric Antigen Receptor T-Cell Immunotherapy
22%
Overall Survival
22%
B Cell Maturation Antigen
20%
Hematologic Malignancy
18%
Infection
18%
AL Amyloidosis
18%
Neoplasm
17%
Progression Free Survival
15%
Myeloid Malignancy
15%
Biological Marker
13%
Toxicity and Intoxication
11%
Clinical Trial
11%
Cytopenia
10%
Acute Myeloid Leukemia
10%
Antibody Response
10%
Disease Exacerbation
10%
Second Cancer
10%
Plasma Exchange
10%
Ascorbic Acid Deficiency
10%
COVID-19 Vaccination
10%
Stem Cell
10%
CAR T-cell therapy
10%
Cardiac Troponin
10%
Race Difference
10%
Pancreas Adenocarcinoma
10%
Targeted Therapy
10%
Immunoglobulin G Antibody
10%
Ascorbic Acid
10%
Immunoglobulin Domain
10%
Cytokine Release Syndrome
10%
Translational Research
10%
Heart Amyloidosis
10%
Natriuretic Factor
10%
Myeloma Cast Nephropathy
10%
Lymphocyte
10%
Hazard Ratio
9%
Leukemia
8%
Chimeric Antigen Receptor
8%
Matrix Metalloproteinase
6%
Programmed Death-Ligand 1
6%
Autoimmunity
6%
Clinical Research
6%
Lymphoma
6%
Odds Ratio
6%
COVID-19 Vaccine
5%
Effector Cell
5%
Keyphrases
Multiple Myeloma
50%
Idecabtagene Vicleucel
41%
Real-world Experience
30%
Hematological Malignancies
28%
Chimeric Antigen Receptor T-cell Therapy
22%
Relapsed or Refractory multiple Myeloma
21%
Overall Survival
18%
Myeloid Malignancies
15%
Ide-cel
14%
Clinical Outcomes
13%
Leukemia Patients
11%
Myeloid Neoplasms
11%
Hazard Ratio
10%
Extramedullary Disease
10%
Therapeutic Plasma Exchange
10%
Clinical Characteristics
10%
SARS-CoV-2 Vaccination
10%
Two-dose
10%
Renal Response
10%
C-level
10%
Second Primary Malignancy
10%
Therapeutic Target
10%
Single Center
10%
Natriuretic Peptides
10%
Racial Differences
10%
Kinase Inhibitor
10%
Acute Myeloid Leukemia Stem Cells
10%
Translational Research
10%
Targeted Therapy
10%
Kinase Inhibitor Therapy
10%
Molecular Characteristics
10%
Cardiac Amyloidosis
10%
Pancreatic Adenocarcinoma
10%
CAR T-cell Therapy
10%
Amyloid Light Chain
10%
Light Chain Amyloidosis
10%
Immunoglobulin Domain
10%
Chronic Lymphocytic Leukemia
10%
Cardiac Troponin
10%
Disease Risk
10%
Immune Checkpoint Blockade
10%
Transmembrane Domain
10%
Vitamin C Deficiency
10%
Ethnic Differences
10%
Marker of Disease Progression
10%
Transplantation
10%
IgG Antibody Response
10%
Renal Impairment
10%
Myeloma Cast Nephropathy
10%
Global Longitudinal Strain
10%
Pharmacology, Toxicology and Pharmaceutical Science
Multiple Myeloma
70%
Malignant Neoplasm
30%
Overall Survival
23%
Disease
21%
B Cell Maturation Antigen
20%
Progression Free Survival
18%
AL Amyloidosis
18%
Infection
17%
Chimeric Antigen Receptor
14%
Biological Marker
12%
Disease Exacerbation
12%
Matrix Metalloproteinase
12%
Clinical Research
11%
Bortezomib
10%
Troponin
10%
Digestive System Cancer
10%
Pancreas Adenocarcinoma
10%
microRNA
10%
Neoplasm
10%
Chronic Lymphatic Leukemia
10%
Phosphotransferase Inhibitor
10%
Natriuretic Factor
10%
Heart Amyloidosis
10%
Clinical Trial
10%
Pancreas Cancer
10%
Amyloid
10%
Myeloma
10%
Immunotherapy
10%
Toxicity and Intoxication
7%
Cytokine Release Syndrome
6%
Symptom
5%
Cohort Study
5%